Artemether/Lumefantrine = AL oral
Co-artemether guidance for uncomplicated malaria and completion treatment after severe malaria, with weight-based 3-day dosing.
Therapeutic action
Antimalarial.
Indications
- Treatment of uncomplicated falciparum malaria.
- Treatment of uncomplicated malaria due to other Plasmodium species, when chloroquine cannot be used.
- Completion treatment following parenteral therapy for severe malaria.
Forms and strengths
Co-formulated tablets of artemether/lumefantrine in blister packs for a complete treatment for one individual.
There are 5 different blister packs corresponding to 4 different categories of weight.
- 20 mg artemether/120 mg lumefantrine dispersible tablet, blister pack of 6 tablets.
- 20 mg artemether/120 mg lumefantrine dispersible tablet, blister pack of 12 tablets.
- 20 mg artemether/120 mg lumefantrine tablet, blister pack of 18 tablets.
- 20 mg artemether/120 mg lumefantrine tablet, blister pack of 24 tablets.
- 80 mg artemether/480 mg lumefantrine tablet, blister pack of 6 tablets.
Dose and duration
The treatment is administered 2 times daily for 3 days. On D1, the first dose is given at 0 hour and the second dose at 8 to 12 hours. Subsequent doses on D2 and D3 are given 2 times daily in the morning and evening.
| Weight | 20/120 mg tablet | 80/480 mg tablet | ||||
|---|---|---|---|---|---|---|
| D1 | D2 | D3 | D1 | D2 | D3 | |
| 5 to < 15 kg | 1 disp tab x 2 | 1 disp tab x 2 | 1 disp tab x 2 | - | - | - |
| 15 to < 25 kg | 2 disp tab x 2 | 2 disp tab x 2 | 2 disp tab x 2 | - | - | - |
| 25 to < 35 kg | 3 tab x 2 | 3 tab x 2 | 3 tab x 2 | - | - | - |
| ≥ 35 kg | 4 tab x 2 | 4 tab x 2 | 4 tab x 2 | 1 tab x 2 | 1 tab x 2 | 1 tab x 2 |
Weight-based dosing
- 5 to < 15 kg: 1 dispersible 20/120 mg tablet 2 times daily on D1, D2, and D3.
- 15 to < 25 kg: 2 dispersible 20/120 mg tablets 2 times daily on D1, D2, and D3.
- 25 to < 35 kg: 3 tablets of 20/120 mg 2 times daily on D1, D2, and D3.
- >= 35 kg: 4 tablets of 20/120 mg 2 times daily on D1, D2, and D3, or 1 tablet of 80/480 mg 2 times daily on D1, D2, and D3.
Contra-indications, adverse effects, precautions
- May cause headache, dizziness, and gastrointestinal disturbances.
- Administer with caution to patients taking drugs that prolong the QT interval, including amiodarone, other antimalarials, antipsychotics, fluconazole, fluoroquinolones, hydroxyzine, macrolides, and ondansetron.
- If the patient vomits within 30 minutes after administration, re-administer the full dose.
- If the patient vomits between 30 minutes and 1 hour after administration, re-administer half of the dose.
- Pregnancy: no contra-indication.
- Breast-feeding: no contra-indication.
Source
MSF Essential drugs practical guidelines (January 2026)
This page reproduces the structured reference information for this batch while leaving out the Storage and Remarks sections.
Rate this guide
Be the first to rate this guide.